SPY421.97-0.14 -0.03%
DIA338.65-2.11 -0.62%
IXIC14,161.35+121.67 0.87%

BRIEF-Minerva Neurosciences Announces The Results Of The Phase 3 Trial Of Roluperidone For The Treatment Of Negative Symptoms Of Schizophrenia Following The Completion Of The 40-Week Open-Label Extension

05/11/2021 17:01
BRIEF-Minerva Neurosciences Announces The Results Of The Phase 3 Trial Of Roluperidone For The Treatment Of Negative Symptoms Of Schizophrenia Following The Completion Of The 40-Week Open-Label Extension

- Minerva Neurosciences Inc NERV.O:

  • MINERVA NEUROSCIENCES ANNOUNCES THE RESULTS OF THE PHASE 3 TRIAL OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA FOLLOWING THE COMPLETION OF THE 40-WEEK OPEN-LABEL EXTENSION

  • MINERVA NEUROSCIENCES - FAVORABLE SAFETY PROFILE WITH FEW SERIOUS ADVERSE EVENTS & NO EVIDENCE OF SOMNOLENCE, EXTRAPYRAMIDAL SIDE EFFECTS/WEIGHT GAIN

  • MINERVA NEUROSCIENCES INC - LIMITED NUMBER OF RELAPSES OBSERVED OVER ONE YEAR

  • MINERVA NEUROSCIENCES - CONTINUOUS IMPROVEMENT IN NEGATIVE SYMPTOMS AS MEASURED BY PANSS MARDER NSFS OBSERVED OVER ONE YEAR

  • MINERVA NEUROSCIENCES - ROLUPERIDONE AT BOTH DOSES WAS SAFE AND WELL TOLERATED

  • MINERVA NEUROSCIENCES - TREATMENT-EMERGENT ADVERSE EVENTS WERE GENERALLY MILD TO MODERATE IN SEVERITY FOR ROLUPERIDONE

Source text for Eikon: ID:nGNX4HcsM

Further company coverage: NERV.O


(([email protected];))